Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.

Published on Jun 2, 2018in Diabetes & Metabolism6.041
· DOI :10.1016/J.DIABET.2018.05.007
André Scheen96
Estimated H-index: 96
(University of Liège)
Sources
Abstract
Abstract After failure of metformin monotherapy, another glucose-lowering agent should be added to improve glucose control. The clinician has several pharmacological choices, including the addition of a sulphonylurea (SU) or a dipeptidyl peptidase-4 inhibitor (DPP-4i). While the cardiovascular safety of SUs remains a matter of controversy, DPP-4is have proven their non-inferiority vs placebo in recent cardiovascular (CV) outcome trials. In the absence of a head-to-head CV outcome trial—the CAROLINA, comparing linagliptin with glimepiride, is still ongoing—only indirect information can be found in the literature to compare CV outcomes (major CV events, myocardial infarction, ischaemic stroke, CV death and all-cause mortality) in patients with type 2 diabetes mellitus (T2DM) treated with SUs or DPP-4is. Thus, this comprehensive review summarizes the CV outcomes (excluding heart failure) reported in meta-analyses of randomized controlled trials (RCTs) of SUs vs placebo or other glucose-lowering agents, DPP-4is vs placebo or other glucose-lowering agents and SUs vs DPP-4is in phase-II/III studies. Also, the results of observational studies reporting CV events in patients treated with either SUs or DPP-4is have been carefully examined. Overall, the CV safety of SUs appears to be poorer than that of DPP-4is in both RCTs and cohort studies. However, the results are somewhat disparate, and such heterogeneity may be explained by different patient characteristics across studies, but also perhaps by differences between various molecules in each pharmacological class. In particular, some doubt about a class effect affecting SU CV safety has been raised. The results of CAROLINA are expected to shed more light on SU CV concerns, especially compared with DPP-4is.
📖 Papers frequently viewed together
References73
Newest
#1Stephen Colagiuri (USYD: University of Sydney)H-Index: 69
#2David R. Matthews (University of Oxford)H-Index: 83
Last. Michel Marre (Paris Diderot University)H-Index: 90
view all 6 authors...
Abstract The sulfonylureas are effective oral glucose-lowering agents with a long history of clinical use. While all have the same general mechanism of action, their pharmacokinetic properties are influenced by factors such as dosage, rate of absorption, duration of action, route of elimination, tissue specificity, and binding affinity for pancreatic β-cell receptor. The result is a class of agents with similar HbA1c-lowering efficacy, but well-documented differences in terms of effects on hypog...
Source
#1Kang Chen (Chinese PLA General Hospital)H-Index: 1
#2Deying Kang (Sichuan University)H-Index: 1
Last. Yiming Mu (Chinese PLA General Hospital)H-Index: 23
view all 7 authors...
We performed a meta-analysis of randomized controlled trials (RCTs) to compare the long-term glycemic durability between dipeptidyl-peptidase 4 (DPP4) inhibitors and sulfonylureas (SUs) in patients with type 2 diabetes mellitus (T2DM), in terms of the changes in glycosylated hemoglobin (HbA1c) levels from an intermediate time point (26 weeks or 52 weeks) to 104 weeks of treatment. The Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library) databases were searched for relevant RCTs. Eight ...
Source
#1Judith van Dalem (PHRI: Public Health Research Institute)H-Index: 2
#2Martijn C. G. J. Brouwers (Maastricht University Medical Centre)H-Index: 21
Last. Andrea M. Burden (PHRI: Public Health Research Institute)H-Index: 18
view all 8 authors...
We investigated the association between the current use of individual sulphonylureas and the risk of a first ever acute myocardial infarction (AMI) and all-cause mortality, in a population-based cohort study using primary care data from the Clinical Practice Research Datalink (CPRD) database (2004-2012). New users (N=121,869) with at least one prescription for a non-insulin antidiabetic agent, and aged ≥18 years were included. The first prescription defined start of follow-up. Time-dependent Cox...
Source
#1Charles E. Leonard (UPenn: University of Pennsylvania)H-Index: 24
#2Colleen M. Brensinger (UPenn: University of Pennsylvania)H-Index: 71
Last. Sean Hennessy (UPenn: University of Pennsylvania)H-Index: 58
view all 10 authors...
OBJECTIVE To examine the association between individual antidiabetic sulfonylureas and outpatient-originating sudden cardiac arrest and ventricular arrhythmia (SCA/VA). RESEARCH DESIGN AND METHODS We conducted a retrospective cohort study using 1999–2010 U.S. Medicaid claims from five large states. Exposures were determined by incident use of glyburide, glimepiride, or glipizide. Glipizide served as the reference exposure, as its effects are believed to be highly pancreas specific. Outcomes were...
Source
ABSTRACTIntroduction: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are generally considered as glucose-lowering agents with a safe profile in type 2 diabetes.Areas covered: An updated review of rece...
Source
#1Elisabetta Patorno (Brigham and Women's Hospital)H-Index: 32
#2Allison B. Goldfine (Harvard University)H-Index: 69
Last. Seoyoung C. Kim (Brigham and Women's Hospital)H-Index: 43
view all 7 authors...
ABSTRACT Objective To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA), or sulfonylureas, as used in routine practice. Design Population based retrospective cohort study. Setting Nationwide sample of patients with type 2 diabetes from a large de-identified US commercial healthcare database (Optum Clinformatics Datama...
Source
#1Carolyn F. Deacon (UCPH: University of Copenhagen)H-Index: 87
: The first clinical study to investigate effects of dipeptidyl peptidase-4 (DPP-4) inhibition was published in 2002, and since then, numerous randomized controlled trials (RCTs) have shown that DPP-4 inhibitors are efficacious, safe and well-tolerated. This review will focus upon RCTs which have investigated DPP-4 inhibitors in patient groups which are often under-represented or excluded from typical phase 3 clinical trials. Large cardiovascular (CV) safety outcome trials in patients with estab...
Source
#1Alan J. Garber (BCM: Baylor College of Medicine)H-Index: 60
#2Martin J. Abrahamson (Harvard University)H-Index: 23
Last. Guillermo E. Umpierrez (Emory University)H-Index: 6
view all 20 authors...
Abbreviations: A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACEI = angiotensin-converting enzyme inhibitor; ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ASCVD = atherosclerotic cardiovascular disease; BAS = bile...
Source
#1Tongtong Wang (MSD: Merck & Co.)H-Index: 6
#2Ann Marie Mcneill (MSD: Merck & Co.)H-Index: 11
Last. Samuel S. Engel (MSD: Merck & Co.)H-Index: 40
view all 5 authors...
Introduction Previous analyses concluded that patients initiating treatment with sitagliptin are older and have more comorbidities than patients initiating treatment with other oral antihyperglycemic agents (OAHAs). However, these studies focused on the general population or subjects ≤ 65 years of age. We sought to compare differences in baseline characteristics of elderly patients (≥ 65 years of age) with T2DM initiating sitagliptin vs. non-DPP-4 inhibitor (non-DPP-4i) OAHA in the MarketScan® M...
Source
#1Shanshan Wu (Capital Medical University)H-Index: 18
#2Andrea Cipriani (Oxford Health NHS Foundation Trust)H-Index: 67
Last. Siyan Zhan (PKU: Peking University)H-Index: 27
view all 11 authors...
ABSTRACTObjective: To evaluate the comparative cardiovascular safety of incretin-based therapies in patients with type 2 diabetes mellitus (T2DM).Methods: Medline, Embase, the Cochrane Library and www.clinicaltrials.gov were searched for randomized controlled trials (RCTs) with duration≥12 weeks. Network meta-analysis was performed, followed by subgroup analysis and meta-regression. The Grading of Recommendations Assessment, Development and Evaluation system was used to assess the quality of evi...
Source
Cited By14
Newest
#1André Scheen (University of Liège)H-Index: 96
Abstract null null Dipeptidyl peptidase-4 inhibitors (DPP-4is) and sodium-glucose cotransporter type 2 inhibitors (SGLT2is) offer new options for the oral management of type 2 diabetes mellitus (T2DM), with the advantage in the elderly population to be devoid of a high risk of hypoglycaemia. SGLT2is have also shown benefits regarding cardiovascular (heart failure) and renal protection, including in patients with T2DM aged ≥ 65 years while DPP-4is have only proved cardiovascular and renal safety ...
Source
#1Jui Wang (NTU: National Taiwan University)H-Index: 9
#2Hon-Yen WuH-Index: 20
Last. Kuo-Liong Chien (NTU: National Taiwan University)H-Index: 65
view all 3 authors...
Abstract null null Aims null Cardiovascular effects of dipeptidyl peptidase-4 inhibitors (DPP4i) versus sulfonylureas (SU) remain controversial in observational studies. This study aimed to evaluate the influence of DPP4i on major adverse cardiovascular events (MACEs), including acute myocardial infarction, cerebrovascular disease, heart failure, cardiogenic shock, malignant dysrhythmia, and revascularisation. null null null Materials and methods null We conducted a nationwide cohort study using...
Source
#1Andrew R. ZulloH-Index: 14
#2Robert J. Smith (Brown University)H-Index: 63
Last. David D. Dore (Brown University)H-Index: 16
view all 8 authors...
Background null Studies comparing dipeptidyl peptidase-4 inhibitors (DPP4Is) to sulfonylureas (SUs) are unavailable for frail older adults, especially nursing home (NH) residents. We examined the effects of DPP4Is versus SUs on severe adverse glycemic events, cardiovascular events, and death among NH residents. null Methods null We conducted a national retrospective cohort study of long-stay NH residents aged ≥65 years using 2008-2010 national US Minimum Data Set clinical assessment data and lin...
Source
#1xin wei (Capital Medical University)
Last. xin liu (Capital Medical University)
view all 0 authors...
BACKGROUND Dipeptidyl peptidase-4 inhibitors (DPP-4i) provide a unique antihyperglycemic effect by regulating incretin peptides in type 2 diabetes mellitus (T2DM) patients who are inadequately controlled with insulin therapy. The aim of this study was to investigate the impact of DPP-4i on leptin concentrations in subjects with T2DM. METHODS Randomized controlled trials (RCTs) with comparators were systematically searched through PubMed, Embase, and the Cochrane Library. Quantitative analysis wa...
Source
#1So Hee Park (SKKU: Sungkyunkwan University)H-Index: 1
#2Han Eol Jeong (SKKU: Sungkyunkwan University)H-Index: 4
Last. Ju-Young Shin (SKKU: Sungkyunkwan University)H-Index: 27
view all 7 authors...
BACKGROUND Cardiovascular safety of evogliptin, a novel dipeptidyl peptidase-4 inhibitor (DPP-4i), remains unclear with limited real-world evidence available on its use. We aimed to assess whether the use of evogliptin was associated with an increased risk of cardiovascular events when compared to glimepiride in patients with type 2 diabetes mellitus (T2DM). METHODS We conducted a population-based cohort study using South Korea's nationwide healthcare database from 1 January 2014 to 31 December ...
Source
#1Yousef Al-Saleh (King Saud bin Abdulaziz University for Health Sciences)H-Index: 17
#2Shaun Sabico (KSU: King Saud University)H-Index: 31
Last. Nasser M. Al-Daghri (KSU: King Saud University)H-Index: 60
view all 13 authors...
Since their inception in the commercial market in the mid-twentieth century, sulfonylureas (SUs) have remained a therapeutic option in the management of type 2 diabetes (T2D). Despite their established glucose-lowering effects, there is no consensus among global experts and modern guidelines regarding the priority of SUs in relation to other therapeutic options, given the lack of evidence that SUs are associated with a low risk of macrovascular events and excess mortality. However, findings from...
Source
Introduction : An increasing number of older patients have type 2 diabetes and are treated with different oral antidiabetic agents whose safety may raise concern considering some particularities of a heterogeneous elderly population. Areas covered : This article discusses some characteristics of older patients that could increase the risk of adverse events, with a focus on hypoglycemia. It describes the most frequent and/or severe complications reported in the elderly in both randomized controll...
Source
Resume Les sulfamides hypoglycemiants (SU) ont longtemps occupe une place essentielle dans le traitement du diabete de type 2 (DT2). La commercialisation de nouveaux antidiabetiques oraux, d’abord les inhibiteurs de la DPP-4 (gliptines), puis les inhibiteurs des SGLT2 (gliflozines), a fortement modifie la donne. En effet, contrairement aux SU, ces medicaments, certes beaucoup plus couteux, offrent l’avantage d’etre associes a un risque minimal d’hypoglycemies et de ne pas faire prendre du poids....
Source
Abstract Sulphonylureas (SUs) for a long time occupied an essential role in the management of type 2 diabetes (T2D) as an alternative or a complement to metformin. However, the launch of new oral antidiabetic drugs (OADs), firstly DPP-4 inhibitors (gliptins) and more recently SGLT2 inhibitors (gliflozins), has markedly changed the scene. Indeed, in contrast to SUs, these new OADs (of course more expensive) offer the advantage of a very low risk of hypoglycaemia and a beneficial impact on bodywei...
Source
#1Emilienne QuilotH-Index: 1
#2Jean-Michel Petit (University of Burgundy)H-Index: 33
Last. Benjamin Bouillet (University of Burgundy)H-Index: 10
view all 4 authors...
BACKGROUND Diabetes management has not been evaluated in French nursing homes (NHs) for 10 years. OBJECTIVES The present study aimed to compare the management of diabetes with guidelines in older patients living in NHs. DESIGN Observational, retrospective and multicentre study carried out in 13 NH in the Cote d'Or region of France. SETTINGS AND SUBJECTS Between January and June 2018, all NH residents older than 65 years and known to have diabetes (n = 148) were included. METHODS Epidemiological,...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.